Marksans Pharma Limited has been assigned an ESG Score of 56 for fiscal 2026 by CRISIL ESG Ratings & Analytics Ltd, a SEBI-licensed ESG Rating Provider (ERP).

The company disclosed the rating to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

According to Marksans Pharma, the score was based on a voluntary review by CRISIL, using information available in the public domain. The company said it received the ESG assessment through the BSE Limited.

The ESG score is available on the BSE website under the company’s intermediaries section.

The disclosure was signed by Harshavardhan Panigrahi, Company Secretary and Compliance Officer, Marksans Pharma.